SCHEMBL310642

SCHEMBL310642

CCOc1cc(N2CCN(C3CCN(CCF)CC3)CC2)ccc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KMT2A Q03164 3/20 0.44
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
HTR4 Q13639 2/20 0.39
GAA P10253 1/20 0.38
RAD52 P43351 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TP53BP1 Q12888 1/20 0.37
L3MBTL3 Q96JM7 1/20 0.37
INSR P06213 1/20 0.37
IGF1R P08069 1/20 0.37
ALK Q9UM73 1/20 0.37
LGMN Q99538 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310764 0.96 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2KMT2AMAPTMEN1
SCHEMBL310656 0.89 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2KMT2AMAPTHTR4
SCHEMBL310840 0.86 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2KMT2AMAPTMEN1
SCHEMBL12917658 0.85 ALK (0.47) ALDH1A1KMT2AMAPTMEN1GAA
SCHEMBL311282 0.84 TGFBR1 (0.41) ALDH1A1SMN1; SMN2L3MBTL1TP53BP1L3MBTL3
SCHEMBL310377 0.84 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KMT2AMAPTMEN1
SCHEMBL10290711 0.84 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KMT2AMAPTMEN1
SCHEMBL10257012 0.84 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2KMT2AMAPTMEN1
SCHEMBL10290595 0.83 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2KMT2AMAPTMEN1
SCHEMBL310692 0.83 MAPT (0.61) ALDH1A1SMN1; SMN2KMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 EP disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 ALDH1A1 3410/4885SMN1; SMN2 2982/4885KMT2A 800/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 ALDH1A1 3410/4885SMN1; SMN2 2982/4885KMT2A 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.